FTH, US81728A2078

Faeth Therapeutics stock heads into an October 6 cancer event

Published on 10/04/2026 at 18:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Faeth Therapeutics stock was last at USD 28.35 on October 2, 2026, as a virtual PIKTOR event approaches. Second-quarter net loss reached USD 16.0 million.

FTH, US81728A2078, Illustration mit AI erstellt.

Faeth Therapeutics (ISIN US81728A2078) stock was last at USD 28.35 on Nasdaq on October 2, 2026, up 0.28 percent from the prior close. The company will host a virtual key opinion leader event on October 6, 2026, to discuss PIKTOR and its Phase 2 endometrial cancer program, according to Faeth Therapeutics in its September 8, 2026 release.

PIKTOR event sets the next checkpoint

The October 6 event will examine the PAM pathway and the combination of serabelisib with sapanisertib. Faeth is evaluating PIKTOR in the Phase 2 FTH-PIK-201 trial for second-line advanced endometrial cancer, with topline data anticipated by year-end 2026, the company said in the same September 8, 2026 release.

The program is also being tested in a Phase 1b/2 study for HR-positive, HER2-negative advanced breast cancer. Faeth reported that the first patient in that study was dosed in April 2026, with interim data anticipated in 2027.

Second-quarter loss widens the funding lens

For the quarter ended June 30, 2026, Faeth reported a net loss of USD 16.007 million, compared with USD 4.936 million a year earlier, while diluted loss per share was USD 0.62. Operating expenses totaled USD 18.385 million, including USD 9.180 million in research and development, according to StockTitan on the companys June 30, 2026 results.

Cash and cash equivalents stood at USD 26.903 million, while marketable securities totaled USD 159.538 million on June 30, 2026. That USD 186.441 million combined liquidity is a key counterweight to the clinical timetable because the companys release lists additional financing and trial execution among its risks.

Analysts see room above USD 28.35

MarketBeat lists a Moderate Buy consensus from 15 analysts, with an average price target of USD 56.25, a high target of USD 70.00 and a low target of USD 50.00. The average target lies 98.4 percent above the October 2, 2026 Nasdaq price of USD 28.35.

Faeth Therapeutics stock carried a market capitalization of USD 732.6 million and traded 187,921 shares on October 2, 2026. The 52-week range was USD 7.45 to USD 42.14, placing the last price 32.7 percent below the yearly high.

Faeth Therapeutics stock approaches October 6

Faeth Therapeutics stock was last at USD 28.35 on Nasdaq on October 2, 2026, with the October 6 event and the year-end Phase 2 readout forming the next dated clinical checkpoints.